Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Barbara Sarholz
Observed names:
B. Sarholz,
Sarholz, Barbara
Institution:
Merck Healthcare KGaA, Darmstadt (Germany)
Observed institutions:
University of Hohenheim,
Merck KGaA, Darmstadt (Germany),
General Motors (Germany),
Merck Healthcare KGaA, Darmstadt (Germany)
ORCID:
0009-0003-1175-8685
Observed ORCID:
0009-0003-1175-8685
OpenAlex ID:
A5037724392
A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours
2020
·
Mark T. J. van Bussel
, Ahmad Awada
, et al.
·
British Journal of Cancer
·
138
PDF
Heterosis in early seed development: a comparative study of F1 embryo and endosperm tissues 6 days after fertilization
2009
·
Stephanie Jahnke
, Barbara Sarholz
, et al.
·
Theoretical and Applied Genetics
·
107
Analysis of nonadditive protein accumulation in young primary roots of a maize ( Zea mays L.) F 1 ‐hybrid compared to its parental inbred lines
2008
·
Nadine Hoecker
, Tobias Lamkemeyer
, et al.
·
PROTEOMICS
·
99
A Phase 1 Study of the DNA-PK Inhibitor Peposertib in Combination With Radiation Therapy With or Without Cisplatin in Patients With Advanced Head and Neck Tumors
2023
·
Michael Samuels
, Johan Falkenius
, et al.
·
International Journal of Radiation Oncology*Biology*Physics
·
80
Validation of candidate genes putatively associated with resistance to SCMV and MDMV in maize (Zea mays L.) by expression profiling
2009
·
Anna Użarowska
, Giuseppe Dionisio
, et al.
·
BMC Plant Biology
·
74
PDF
A Phase Ib Study of the DNA-PK Inhibitor Peposertib Combined with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
2023
·
Paul B. Romesser
, Jaume Capdevila
, et al.
·
Clinical Cancer Research
·
43
PDF
Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumors
2020
·
Kohei Shitara
, Kentaro Yamazaki
, et al.
·
Japanese Journal of Clinical Oncology
·
35
PDF
Safety, clinical activity and pharmacological biomarker evaluation of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814: Results from two phase I trials
2018
·
M. Mau-Sorensen
, M. van Bussel
, et al.
·
Annals of Oncology
·
20
Efficacy, safety, biomarkers, and phase II dose modeling in a phase I trial of the oral selective c-Met inhibitor tepotinib (MSC2156119J).
2015
·
Gerald Steven Falchook
, Razelle Kurzrock
, et al.
·
Journal of Clinical Oncology
·
13
Weekly and every 2 weeks cetuximab maintenance therapy after platinum-based chemotherapy plus cetuximab as first-line treatment for non-small cell lung cancer: randomized non-comparative phase IIIb NEXT trial
2014
·
David F. Heigener
, José Rodrigues Pereira
, et al.
·
Targeted Oncology
·
10
A multicenter phase Ib/II study of DNA-PK inhibitor peposertib (M3814) in combination with capecitabine and radiotherapy in patients with locally advanced rectal cancer.
2021
·
Paul Bernard Romesser
, Emma B. Holliday
, et al.
·
Journal of Clinical Oncology
·
9
A multicenter phase Ib/II study of DNA-PK inhibitor peposertib (M3814) in combination with capecitabine and radiotherapy in patients with locally advanced rectal cancer.
2020
·
Paul Bernard Romesser
, Emma B. Holliday
, et al.
·
Journal of Clinical Oncology
·
7
Phase I, first-in-human trial of Bruton’s tyrosine kinase inhibitor M7583 in patients with B-cell malignancies
2021
·
Wojciech Jurczak
, Simon Rule
, et al.
·
Leukemia & lymphoma/Leukemia and lymphoma
·
5
Variance Component Estimation for Mixed Model Analysis of cDNA Microarray Data
2008
·
Barbara Sarholz
, Hans‐Peter Piepho
·
Biometrical Journal
·
5
First in Human, Phase I/II Trial of the Bruton's Tyrosine Kinase Inhibitor (BTKi) M7583 in Patients with B Cell Malignancies: Study Design and Initial Outcomes
2017
·
Wojciech Jurczak
, Simon Rule
, et al.
·
Blood
·
4
First-Line Cetuximab with Folfox or Folfiri Every 2 Weeks in Kras Wild-Type Metastatic Colorectal Cancer: Phase II Apec Study
2013
·
Ann-Lii Cheng
, Gerardo Cornelio
, et al.
·
Annals of Oncology
·
4
A phase II, multicenter, open-label, single-arm study of berzosertib plus topotecan in patients with relapsed platinum-resistant small-cell lung cancer (DDRiver SCLC 250)
2025
·
A. Navarro
, A. Thomas
, et al.
·
ESMO Open
·
3
104TiP Phase Ib/IIa study of ATR inhibitor tuvusertib + anti-PD-1 cemiplimab in patients with advanced non-squamous (nsq) non-small cell lung cancer (NSCLC) that has progressed on prior anti-PD-(L)1 and platinum-based therapies
2024
·
L. Paz-Ares
, F. Cappuzzo
, et al.
·
ESMO Open
·
3
1666TiP Phase II study of berzosertib (M6620) + topotecan in patients with relapsed platinum-resistant SCLC: DDRiver SCLC 250
2021
·
A. Thomas
, F. Cappuzzo
, et al.
·
Annals of Oncology
·
3
A Phase I/II, First in Human Trial of the Bruton's Tyrosine Kinase Inhibitor M7583 in Patients with B-Cell Malignancies
2018
·
Wojciech Jurczak
, Simon Rule
, et al.
·
Blood
·
3
Phase I/II, first in human trial with M7583, a Bruton’s tyrosine kinase inhibitor (BTKi), in patients with B cell malignancies
2018
·
W. Jurczak
, S. Rule
, et al.
·
Annals of Oncology
·
3
Phase I/II, first in human trial of the Bruton’s tyrosine kinase inhibitor (BTKi) M7583 in patients with B cell malignancies.
2017
·
Simon Rule
, David Tucker
, et al.
·
Journal of Clinical Oncology
·
2
P-118 Tepotinib (MSC2156119J) monotherapy in patients with MET-positive advanced hepatocellular carcinoma with Child-Pugh Class A liver function who have failed sorafenib treatment: phase Ib/II trial
2015
·
S. Faivre
, E. Raymond
, et al.
·
Annals of Oncology
·
2
1534P Phase II study of berzosertib + topotecan in patients with relapsed platinum (Pt)-resistant SCLC (DDRiver SCLC 250): Japanese safety run-in
2022
·
T. Yoshida
, Y. Fujisaka
, et al.
·
Annals of Oncology
·
1
Phase Ib/Ii, Multicenter, Single-Arm Trial of the Oral C-Met Inhibitor Msc2156119J As Monotherapy in Patients with Met-Positive Advanced Hepatocellular Carcinoma with Child-Pugh Class a Liver Function Who Failed Sorafenib Treatment
2014
·
S. Faivre
, B. Sarholz
, et al.
·
Annals of Oncology
·
1
Show more works
View as search
Works count:
48
Citation count:
675
H-index:
10
I10-index:
10
Year
Topic
Type